Screener
Spyre Therapeutics, Inc. SYRE Total debt
Discontinued — last reported Q2 '23
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $4.33M.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed August 11, 2023. Open the filing →
- Filed
- Aug 11, 2023
- Fiscal quarter
- Q2 FY2023
- Calendar quarter
- Q2 2023
- Accession
- 0000950170-23-041590
FAQ
- What is Spyre Therapeutics, Inc.'s total debt?
- Spyre Therapeutics, Inc. (SYRE) reported total debt of $4.33M in Q2 2023.
- How has Spyre Therapeutics, Inc.'s total debt changed year-over-year?
- Spyre Therapeutics, Inc.'s total debt decreased by 9.6% year-over-year, from $4.79M to $4.33M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total debt?
- Over 2 years (2020 to 2022), Spyre Therapeutics, Inc.'s total debt has grown at a -8.3% compound annual growth rate (CAGR), from $5.52M to $4.65M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about Spyre Therapeutics, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude